Egle A - Search Results

1

The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.

Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Egle A, Pichler M. Troppan KT, et al. Among authors: egle a. Eur J Haematol. 2015 Dec;95(6):538-44. doi: 10.1111/ejh.12529. Epub 2015 Mar 26. Eur J Haematol. 2015. PMID: 25677782

2

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Egle A, Marschitz I, Posch B, Herold M, Greil R. Egle A, et al. Br J Haematol. 1996 Jul;94(1):211-2. Br J Haematol. 1996. PMID: 8757538 No abstract available.

3

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R. Egle A, et al. Eur J Immunol. 1996 Dec;26(12):3119-26. doi: 10.1002/eji.1830261244. Eur J Immunol. 1996. PMID: 8977313

4

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R. Egle A, et al. Br J Haematol. 1997 May;97(2):418-28. doi: 10.1046/j.1365-2141.1997.382680.x. Br J Haematol. 1997. PMID: 9163609 Free article.

5

Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.

Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R. Villunger A, et al. Among authors: egle d, egle a. Br J Haematol. 1998 Sep;102(4):1069-80. doi: 10.1046/j.1365-2141.1998.00880.x. Br J Haematol. 1998. PMID: 9734660 Free article.

6

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.

Greil R, Egle A, Villunger A. Greil R, et al. Among authors: egle a. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.

7

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle A, Steurer M, Greil R. Tinhofer I, et al. Among authors: egle a. Blood. 2006 Nov 1;108(9):2950-6. doi: 10.1182/blood-2006-03-010553. Epub 2006 Jul 6. Blood. 2006. PMID: 16825496 Free article.

8

PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

Holler C, Piñón JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A. Holler C, et al. Among authors: egle a. Blood. 2009 Mar 19;113(12):2791-4. doi: 10.1182/blood-2008-06-160713. Epub 2009 Jan 23. Blood. 2009. PMID: 19168795 Free article.

9

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Pleyer L, Egle A, Hartmann TN, Greil R. Pleyer L, et al. Among authors: egle a. Nat Rev Clin Oncol. 2009 Jul;6(7):405-18. doi: 10.1038/nrclinonc.2009.72. Epub 2009 Jun 2. Nat Rev Clin Oncol. 2009. PMID: 19488076 Review.

10

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

Hartmann TN, Pleyer L, Desch P, Egle A, Greil R. Hartmann TN, et al. Among authors: egle a. Discov Med. 2009 Oct;8(42):157-64. Discov Med. 2009. PMID: 19833065 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters